Marker Therapeutics, Inc. Common Stock (MRKR)
Marker Therapeutics, Inc. is a biotechnology company focused on the development of targeted T-cell therapies for cancer. Utilizing its proprietary MultiVax platform, the company designs and manufactures personalized immunotherapies aimed at activating the patient's immune system to fight various cancers. Founded to advance innovative cancer treatment options, Marker Therapeutics aims to improve outcomes for patients with difficult-to-treat tumors.
Company News
Marker Therapeutics announced CEO Dr. Juan Vera will participate in a fireside chat at the H.C. Wainwright conference on September 10, 2025, discussing their Multi-Antigen Recognizing (MAR) T cell platform and recent clinical developments.
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly. NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares climbed 62.9% to $1.01 after the company granted Biostem Technologies the right ...
Use these tips if you're using fundamental analysis to trade penny stocks The post Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?